### 2024 Current Fiscal Year Report: Advisory Council on Blood Stem Cell **Transplantation**

Report Run Date: 04/19/2024 03:51:49 AM

1. Department or Agency 2. Fiscal Year

Department of Health and Human

Services

3b. GSA

2024

3. Committee or Subcommittee

Committee No.

Advisory Council on Blood Stem Cell

Transplantation

31442

4. Is this New During 5. Current 6. Expected 7. Expected

Fiscal Year? Charter Renewal Date Term Date

No 02/19/2023 02/19/2025

8b. Specific 8a. Was Terminated During 8c. Actual Termination

FiscalYear? Term Date

Authority

No

9. Agency 10b.

10a. Legislation **Recommendation for Next** Legislation Req to Terminate? Pending? **FiscalYear** 

Continue Not Applicable Not Applicable

**11. Establishment Authority** Statutory (Congress Created)

12. Specific 13. 14

14c. Establishment Effective Commitee Presidential?

Authority **Type** Date

12/20/2005 Continuing 42 U.S.C. 274k No

**15. Description of Committee** Non Scientific Program Advisory

Board

16a. Total

No Reports for Number of this FiscalYear

Reports

17a.

0 17b. Closed 0 17c. Partially Closed 0 Other Activities 0 17d. Total 0 Open

**Meetings and Dates** 

No Meetings

	<b>Current Next</b>	
	FY	FY
18a(1). Personnel Pmts to	\$0.0	00\$0.00
Non-Federal Members	ψ0.0	ο φυ.υυ
18a(2). Personnel Pmts to	\$0.0	00\$0.00
Federal Members	ψ0.0	ο φο.σσ
18a(3). Personnel Pmts to	\$0.0	00\$0.00
Federal Staff	ψ0.0	ο φυ.συ
18a(4). Personnel Pmts to	\$0.0	00\$0.00
Non-Member Consultants	ψ0.0	ο φο.σσ
18b(1). Travel and Per Diem to	\$0.0	00\$0.00
Non-Federal Members	ψ0.0	σφο.σσ
18b(2). Travel and Per Diem to	\$0.0	00\$0.00
Federal Members	ψ0.0	ο φυ.συ
18b(3). Travel and Per Diem to	\$0.0	00\$0.00
Federal Staff	ΨΟ.	, ο φο.σο
18b(4). Travel and Per Diem to	\$0.0	00\$0.00
Non-member Consultants	Ψοιτ	, σ φσ.σσ
18c. Other(rents,user charges,	\$0.0	00\$0.00
graphics, printing, mail, etc.)	Ψοιτ	, σ φσ.σσ
18d. Total	\$0.0	00\$0.00
19. Federal Staff Support Years	0.0	00.00
(FTE)	0.0	, 0.00

# 20a. How does the Committee accomplish its purpose?

The ACBSCT was established to advise the Secretary of HHS on matters related to the activities of the C.W. Bill Young Cell Transplantation and the National Cord Blood Inventory Programs. The ACBSCT provides a consolidated, comprehensive source of expert, unbiased analysis and recommendations to the Secretary on the latest advances in the science of blood stem cell transplantation, including cord blood.

### 20b. How does the Committee balance its

### membership?

The Council is composed of up to 15 voting members representing marrow donor and transplant centers; cord blood banks; birthing hospitals; transplant recipients; persons waiting for transplants; family members of recipients; and members of the general public. The Council has 4 ex-officio, non-voting members.

## 20c. How frequent and relevant are the Committee Meetings?

The Advisory Council shall convene at least two times each calendar year.

# **20d.** Why can't the advice or information this committee provides be obtained elsewhere? This expertise is not available within HHS.

# 20e. Why is it necessary to close and/or partially closed committee meetings?

#### 21. Remarks

Max number of members changed from 25 to 19 in alignment with current charter (15 members and 4 ex-officios). Sridhar Basavaraju's term end date changed to 9/30/2023.

### **Designated Federal Officer**

Shelley Grant Branch Chief, BSCTB, Division of Transplantation, Health Systems Bureau

Committee Members	Start	End	Occupation	Member Designation
Barker, Juliet	08/12/2022	11/05/2024	Memorial Sloan-Kettering Cancer Center	Special Government Employee (SGE) Member
Berkey, Ann	12/04/2022	12/03/2024	CEO, Berkey Group	Special Government Employee (SGE) Member

DiFronzo, Nancy	01/01/2017	01/01/2024	National Institutes of Health	Ex Officio Member Special
Finney, Marcie	08/12/2022	11/05/2024	Cleveland Cord Blood Center	Government Employee (SGE) Member
Grogl, Max	09/02/2022	09/01/2025	Department of Defense - Navy	Ex Officio Member
Holloman, Frank	01/01/2017	01/01/2024	Health Resources and Services Administration	Ex Officio Member
Jacob, Eapen	12/04/2022	12/03/2024	Medical Director, Human Cellular Therapy Laboratory at Mayo Clinic	Special Government Employee (SGE) Member
Khuu, Hanh	09/02/2022	09/01/2025	Food and Drug Administration	Ex Officio Member
Levine, John	08/12/2022	11/05/2024	Director, Blood and Marrow Transplant Clinical Research	Special Government Employee (SGE) Member
Majhail, Navneet	08/12/2022	11/05/2024	Sarah Cannon Transplant and Cellular Therapy Network	Special Government Employee (SGE) Member
Maziarz, Richard	12/04/2022	12/03/2024	Clinical Researcher	Special Government Employee (SGE) Member
Milano, Filippo	08/12/2022	11/05/2024	Director, Cord Blood Transplantation Program	Special Government Employee (SGE) Member

**Number of Committee Members Listed: 12** 

### **Narrative Description**

HHS has a vital role in safeguarding and promoting public health by overseeing the operation of the C.W. Bill Young Transplantation Program and the National Cord Blood Inventory. The principal purpose of these programs is to make blood stem cells from adult donors and cord blood units available for patients who need a transplant to treat life-threatening conditions, such as leukemia, and who lack a suitably matched relative who can be the donor.

## What are the most significant program outcomes associated with this committee?

Checked if	
Applies	
	✓
	✓
	✓
	✓
	✓
	✓
	✓
	Applies

#### **Outcome Comments**

N/A

### What are the cost savings associated with this committee?

	Checked if Applies
None	✓
Unable to Determine	
Under \$100,000	
\$100,000 - \$500,000	
\$500,001 - \$1,000,000	
\$1,000,001 - \$5,000,000	
\$5,000,001 - \$10,000,000	
Over \$10,000,000	
Cost Savings Other	

### **Cost Savings Comments**

While the ACBSCT's recommendations have focused on improvements to patient care through blood stem cell transplant and efficiency in the system, direct cost savings for the government have not been measured.

What is the approximate <u>Number</u> of recommendations produced by this committee for the life of the committee?

#### **Number of Recommendations Comments**

No recommendations were made in FY 2023.

What is the approximate <u>Percentage</u> of these recommendations that have been or will be <u>Fully</u> implemented by the agency?

48%

### % of Recommendations Fully Implemented Comments

The Program and the community are engaged in discussions about the implementation of all recommendations.

What is the approximate <u>Percentage</u> of these recommendations that have been or will be <u>Partially</u> implemented by the agency?

52%

### % of Recommendations Partially Implemented Comments

The Program and the community are engaged in discussions about the implementation of all recommendations.

Does the agency provide the committee with feedback regarding actions taken to
implement recommendations or advice offered?

Yes	✓	No	Not Applicable

### **Agency Feedback Comments**

The Secretary of HHS acknowledges receipt of any recommendations. The public can obtain information on agency feedback at the ACBSCT website:

https://bloodcell.transplant.hrsa.gov/about/advisory\_council/index.html

### What other actions has the agency taken as a result of the committee's advice or recommendation?

	Checked if Applies
Reorganized Priorities	✓
Reallocated resources	
Issued new regulation	
Proposed legislation	
Approved grants or other payments	
Other	

Action Comments N/A	
Is the Committee engaged in the review of No	applications for grants?
<b>Grant Review Comments</b> N/A	
How is access provided to the information	for the Committee's documentation?
	Checked if Applies
Contact DFO	✓
Online Agency Web Site	<b>∀</b>
Online Committee Web Site	<b>Y</b>
Online GSA FACA Web Site	✓
Publications	
Other	
Access Comments N/A	